111 related articles for article (PubMed ID: 21984220)
1. In vitro evaluation of clinical activity and toxicity of anticancer drugs using tumor cells from patients and cells representing normal tissues.
Haglund C; Aleskog A; Nygren P; Gullbo J; Höglund M; Wickström M; Larsson R; Lindhagen E
Cancer Chemother Pharmacol; 2012 Mar; 69(3):697-707. PubMed ID: 21984220
[TBL] [Abstract][Full Text] [Related]
2. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV
Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
[TBL] [Abstract][Full Text] [Related]
3. Human primary renal cells as a model for toxicity assessment of chemo-therapeutic drugs.
Li W; Lam M; Choy D; Birkeland A; Sullivan ME; Post JM
Toxicol In Vitro; 2006 Aug; 20(5):669-76. PubMed ID: 16289493
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
[TBL] [Abstract][Full Text] [Related]
5. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
6. Screening and evaluation of anticancer agents.
Zee-Cheng RK; Cheng CC
Methods Find Exp Clin Pharmacol; 1988 Feb; 10(2):67-101. PubMed ID: 3283480
[TBL] [Abstract][Full Text] [Related]
7. In vitro evaluation of new anticancer drugs, exemplified by vinorelbine, using the fluorometric microculture cytotoxicity assay on human tumor cell lines and patient biopsy cells.
Fridborg H; Nygren P; Dhar S; Csoka K; Kristensen J; Larsson R
J Exp Ther Oncol; 1996 Sep; 1(5):286-95. PubMed ID: 9414416
[TBL] [Abstract][Full Text] [Related]
8. Preclinical antitumor activity of the oral platinum analog satraplatin.
Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
[TBL] [Abstract][Full Text] [Related]
9. Activity of lipoplatin in tumor and in normal cells in vitro.
Arienti C; Tesei A; Ravaioli A; Ratta M; Carloni S; Mangianti S; Ulivi P; Nicoletti S; Amadori D; Zoli W
Anticancer Drugs; 2008 Nov; 19(10):983-90. PubMed ID: 18827563
[TBL] [Abstract][Full Text] [Related]
10. 3-D tumor model for in vitro evaluation of anticancer drugs.
Horning JL; Sahoo SK; Vijayaraghavalu S; Dimitrijevic S; Vasir JK; Jain TK; Panda AK; Labhasetwar V
Mol Pharm; 2008; 5(5):849-62. PubMed ID: 18680382
[TBL] [Abstract][Full Text] [Related]
11. Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system.
Kolfschoten GM; Pinedo HM; Scheffer PG; Schlüper HM; Erkelens CA; Boven E
Gynecol Oncol; 2000 Mar; 76(3):362-8. PubMed ID: 10684711
[TBL] [Abstract][Full Text] [Related]
12. Use of cellular electrical impedance sensing to assess in vitro cytotoxicity of anticancer drugs in a human kidney cell nephrotoxicity model.
Xie F; Xu Y; Wang L; Mitchelson K; Xing W; Cheng J
Analyst; 2012 Mar; 137(6):1343-50. PubMed ID: 22214987
[TBL] [Abstract][Full Text] [Related]
13. Evaluating drug efficacy and toxicology in three dimensions: using synthetic extracellular matrices in drug discovery.
Prestwich GD
Acc Chem Res; 2008 Jan; 41(1):139-48. PubMed ID: 17655274
[TBL] [Abstract][Full Text] [Related]
14. Systematic analysis of the antiproliferative effects of novel and standard anticancer agents in rhabdoid tumor cell lines.
Lünenbürger H; Lanvers-Kaminsky C; Lechtape B; Frühwald MC
Anticancer Drugs; 2010 Jun; 21(5):514-22. PubMed ID: 20147838
[TBL] [Abstract][Full Text] [Related]
15. Ex vivo therapeutic index by drug sensitivity assay using fresh human normal and tumor cells.
Bosanquet AG; Bell PB
J Exp Ther Oncol; 2004 Jul; 4(2):145-54. PubMed ID: 15500009
[TBL] [Abstract][Full Text] [Related]
16. Phenotype-based drug screening in primary ovarian carcinoma cultures identifies intracellular iron depletion as a promising strategy for cancer treatment.
Gullbo J; Fryknäs M; Rickardson L; Darcy P; Hägg M; Wickström M; Hassan S; Westman G; Brnjic S; Nygren P; Linder S; Larsson R
Biochem Pharmacol; 2011 Jul; 82(2):139-47. PubMed ID: 21531212
[TBL] [Abstract][Full Text] [Related]
17. Species differences in troxacitabine pharmacokinetics and pharmacodynamics: implications for clinical development.
Gourdeau H; Leblond L; Hamelin B; Dong K; Ouellet F; Boudreau C; Custeau D; Richard A; Gilbert MJ; Jolivet J
Clin Cancer Res; 2004 Nov; 10(22):7692-702. PubMed ID: 15570003
[TBL] [Abstract][Full Text] [Related]
18. Strategy for the development of novel anticancer drugs.
Saijo N; Tamura T; Nishio K
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S97-101. PubMed ID: 12856152
[TBL] [Abstract][Full Text] [Related]
19. Differential cytotoxic activity of chemotherapy agents on colony-forming cells from human tumors and normal bone marrow in vitro.
Ajani JA; Blaauw AA; Spitzer G; Baker FL; Tomasovic B; Umbach G; Thielvoldt D; Zander AR; Dicke KA
Exp Hematol; 1985; 13 Suppl 16():95-100. PubMed ID: 2580731
[TBL] [Abstract][Full Text] [Related]
20. New imidazole-coordinated chemotherapeutics with low epithelial toxicity.
Ludwig T; Fakih S; Bertram H; Krebs B; Oberleithner H
Cell Biochem Biophys; 2006; 45(1):31-41. PubMed ID: 16679562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]